Spots Global Cancer Trial Database for tki
Every month we try and update this database with for tki cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer | NCT03595644 | Stage IV Non-sm... | SBRT+TKI TKI | 18 Years - 75 Years | Tongji Hospital | |
| Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. | NCT01652469 | Carcinoma, Non-... | Erlotinib Docetaxel | 18 Years - | ETOP IBCSG Partners Foundation | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia | NCT04006847 | Chronic Myeloid... | Eicosapentaenoi... Tyrosine kinase... | 18 Years - | Milton S. Hershey Medical Center | |
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) | NCT01392170 | Leukemia | PEG-IFNá-2a | 16 Years - | M.D. Anderson Cancer Center | |
| Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer | NCT03595644 | Stage IV Non-sm... | SBRT+TKI TKI | 18 Years - 75 Years | Tongji Hospital | |
| Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC | NCT05277844 | Oligometastatic... Non-small Cell ... Driver Mutation | Local Consolida... TKI | 18 Years - 99 Years | Tata Memorial Hospital | |
| NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma | NCT01649180 | Renal Cell Carc... | Axitinib | 18 Years - | PrECOG, LLC. | |
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) | NCT01392170 | Leukemia | PEG-IFNá-2a | 16 Years - | M.D. Anderson Cancer Center | |
| Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | NCT01223027 | Metastatic Rena... | Dovitinib Sorafenib | 18 Years - | Novartis | |
| Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy | NCT02787447 | Lung Adenocarci... | TKI Thoracic Hypofr... Thymosin Alpha ... | 18 Years - 75 Years | First People's Hospital of Hangzhou | |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | NCT00990249 | Leukemia Lymphoma Allogeneic Haem... Acute Lymphobla... | Busulfan Clofarabine Thymoglobulin Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma | NCT03946943 | Soft Tissue Sar... Undifferentiate... | Anlotinib Toripalimab Blood Draw Tumor Specimen ... | 16 Years - | The First Hospital of Jilin University | |
| Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | NCT06320301 | Biliary Tract C... Gemox Chemother... | Adebrelimab + G... | - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma | NCT01585974 | Renal Cell Carc... | No intervention | 18 Years - | Bayer | |
| Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | NCT06320301 | Biliary Tract C... Gemox Chemother... | Adebrelimab + G... | - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | NCT05456256 | Adenocarcinoma ... Carcinoma, Non-... | LP-300 Pemetrexed Carboplatin | 18 Years - | Lantern Pharma Inc. | |
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | NCT03630120 | Thyroid Cancer Thyroid Cancer,... Differentiated ... Papillary Thyro... Follicular Thyr... Poorly Differen... | Lenvatinib Sorafenib Cabozantinib Vandetanib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) | NCT03133546 | Non Small Cell ... | Osimertinib Bevacizumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients | NCT05168527 | Pancreatic Canc... | Fruquintinib,Al... | 18 Years - 80 Years | Fudan University | |
| Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | NCT05000294 | Bile Duct Cance... Gall Bladder Ca... Breast Cancer Neuroendocrine ... Ovarian Cancer Pancreatic Aden... Soft Tissue Sar... Vulvar Cancer Prostate Cancer | Atezolizumab Tivozanib | 18 Years - 99 Years | University of Florida | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure | NCT05135364 | Unresectable He... | Camrelizumab HAIC TKI | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation | NCT00990249 | Leukemia Lymphoma Allogeneic Haem... Acute Lymphobla... | Busulfan Clofarabine Thymoglobulin Stem Cell Trans... | - 65 Years | M.D. Anderson Cancer Center | |
| Effect of 2nd Gen TKI in CML | NCT02222272 | Myeloid Leukemi... | 18 Years - | European Society for Blood and Marrow Transplantation | ||
| Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. | NCT01652469 | Carcinoma, Non-... | Erlotinib Docetaxel | 18 Years - | ETOP IBCSG Partners Foundation | |
| Trial of TRC105 and Sorafenib in Patients With HCC | NCT02560779 | Hepatocellular ... | Carotuximab (TR... Sorafenib | 18 Years - | Tracon Pharmaceuticals Inc. | |
| Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies | NCT05370469 | Lung Cancer EGFR Gene Mutat... EGFR ALK Gene Mutati... RET Gene Mutati... MET Gene Mutati... KRAS Mutation-R... BRAF ROS1 Gene Mutat... | Sensus Smartwat... RX Cap Fitbit Sense Surveys | 18 Years - | University of Virginia | |
| Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers | NCT02098954 | Carcinoma, Non-... EGFR Gene Mutat... | Gemcitabine pla... | 18 Years - 75 Years | Hunan Province Tumor Hospital | |
| Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation | NCT04666259 | Chronic Myeloge... | ABL001 | 18 Years - | Novartis | |
| Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation | NCT06427811 | Philadelphia Ch... | Asciminib | 18 Years - | Novartis | |
| Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study | NCT04401059 | Carcinoma Non-Small-Cell ... Adenocarcinoma | Elemene plus fi... First or third ... | 18 Years - | Hangzhou Normal University | |
| European Stop Tyrosine Kinase Inhibitor Study | NCT01596114 | Chronic Myeloid... | Stopping treatm... | 18 Years - | European LeukemiaNet | |
| Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC | NCT05277844 | Oligometastatic... Non-small Cell ... Driver Mutation | Local Consolida... TKI | 18 Years - 99 Years | Tata Memorial Hospital | |
| A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled | NCT06282991 | Non-Small Cell ... | Lorlatinib | 20 Years - | Pfizer | |
| cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China | NCT02980536 | Nonsmall Cell L... Adenocarcinoma | 18 Years - | Berry Genomics Co., Ltd. | ||
| Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | NCT01223027 | Metastatic Rena... | Dovitinib Sorafenib | 18 Years - | Novartis | |
| Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) | NCT03133546 | Non Small Cell ... | Osimertinib Bevacizumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| Reduction of Cancer Related Fatigue in Patients During TKI Therapy | NCT01645150 | All Tumor Entit... | Progressive str... | 18 Years - 80 Years | German Cancer Research Center | |
| Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors | NCT06161558 | Neoplasms | Erlotinib Lenvatinib Axitinib | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC | NCT02321293 | Lung Cancer | CurcuVIVA™ Tyrosine Kinase... Tyrosine Kinase... | 18 Years - | Lady Davis Institute | |
| TAURAS - T790 AURA ScreenFailure SOC Registry Study | NCT02405247 | Non Small Cell ... | Patient Reporte... | 18 Years - | AstraZeneca | |
| Reduction of Cancer Related Fatigue in Patients During TKI Therapy | NCT01645150 | All Tumor Entit... | Progressive str... | 18 Years - 80 Years | German Cancer Research Center | |
| Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib | NCT03129724 | Kidney Neoplasm... | 18 Years - | University Hospital, Strasbourg, France | ||
| European Stop Tyrosine Kinase Inhibitor Study | NCT01596114 | Chronic Myeloid... | Stopping treatm... | 18 Years - | European LeukemiaNet | |
| Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma | NCT03071705 | Non-Small Cell ... Tyrosine Kinase... EGFR Gene Mutat... | Metformin TKI | 18 Years - 99 Years | Instituto Nacional de Cancerologia de Mexico | |
| Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma | NCT03071705 | Non-Small Cell ... Tyrosine Kinase... EGFR Gene Mutat... | Metformin TKI | 18 Years - 99 Years | Instituto Nacional de Cancerologia de Mexico | |
| Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. | NCT01652469 | Carcinoma, Non-... | Erlotinib Docetaxel | 18 Years - | ETOP IBCSG Partners Foundation | |
| A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants | NCT06221475 | Advanced Non-sm... EGFR Mutation HER2 Mutation Healthy Volunte... | BAY2927088 coat... [14C]-BAY292708... [14C]-BAY292708... | 18 Years - 55 Years | Bayer | |
| A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma | NCT06143579 | Potentially Res... | FOLFOX-HAIC+Len... | 18 Years - | Sun Yat-sen University | |
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) | NCT01392170 | Leukemia | PEG-IFNá-2a | 16 Years - | M.D. Anderson Cancer Center | |
| Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | NCT06320301 | Biliary Tract C... Gemox Chemother... | Adebrelimab + G... | - | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Regorafenib in Patients With Refractory Primary Bone Tumors | NCT05395741 | Osteosarcoma Ewing Sarcoma o... | Regorafenib | 9 Years - 21 Years | Institute of Mother and Child, Warsaw, Poland | |
| Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) | NCT03133546 | Non Small Cell ... | Osimertinib Bevacizumab | 18 Years - | ETOP IBCSG Partners Foundation | |
| A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants | NCT06221475 | Advanced Non-sm... EGFR Mutation HER2 Mutation Healthy Volunte... | BAY2927088 coat... [14C]-BAY292708... [14C]-BAY292708... | 18 Years - 55 Years | Bayer | |
| Reduction of Cancer Related Fatigue in Patients During TKI Therapy | NCT01645150 | All Tumor Entit... | Progressive str... | 18 Years - 80 Years | German Cancer Research Center | |
| Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations | NCT01752920 | Solid Tumor | Derazantinib lo... Derazantinib mi... Derazantinib hi... Derazantinib at... | 18 Years - | Basilea Pharmaceutica | |
| cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China | NCT02980536 | Nonsmall Cell L... Adenocarcinoma | 18 Years - | Berry Genomics Co., Ltd. | ||
| Donafenib Plus Sintilimab for Advanced HCC | NCT05162352 | Hepatocellular ... | Donafenib+sinti... | 18 Years - | Second Affiliated Hospital of Guangzhou Medical University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
